ASH - Ashland Inc. 0 WATCHERS

GLTO GLTO has a scheduled presentation at the ASH ( American Society for Hematology ) DEC 6-8 ( annual event ) #1-An official introduction to their new oncology program #2-precinical data and clinical data & development of GB3226 ( novel inhibitor used for acute leukemia )

MRKR, Dec 6-9th conference - stock will at least double after this if news is good - news is supposed to be good. (post-Alyeska + new board member + ASH this weekend)

**Marker Therapeutics (MRKR)** * Price: \~$1.09 | Market Cap: $18M | Shares Out: 16.7M | EV: $1.25M * Cash Runway: \~9 months (post-$10M ATM raise) | Debt/Equity: \~0.07 (ideal for buyout) **Major Catalysts:** * **ASH 2025 Conference (Dec 6-9)**: Phase 1 APOLLO data presentation (MT-601 MAR-T cells in [r/r](https://www.reddit.com/r/r/) NHL) …

MRKR, Dec 6-9th conference - stock will at least double after this if news is good - news is supposed to be good. (post-Alyeska + new board member + ASH in 1 week)

$SNTI 1.68 -> 2.08 since my last post, Data read-out pending SNTI already showed how wild it can get when hype kicks in: spiked from $2 to $16 intraday back in Dec 2024 on pure speculation and thin float, no real data needed. Now the Dec 8 ASH readout drops …

MRKR, Dec 6-9th conference - stock will at least double after this if news is good - news is supposed to be good. (post-Alyeska + new board member + ASH in 1 week)

CTXR popped. Here’s the why, the how, and what matters next Citius Pharmaceuticals closed about 14.8% higher on Nov 26, then added roughly 5% after hours to 1.40. Volume around 1.9M, day range 1.24 to 1.53. The move lines up with a cluster of positive headlines and a cleaner near-term …

MRKR is a great stock that no-one talks about with upcoming catalyst They have multiple projects, great recent news and upcoming catalyst at dec 6-9 (ASH) They delegated a new board member who was partner at the Takeda Ventures, after that Aleyshka bought up 1.2 million shares, NEA holding 1.7 …

$AUTL Ready for takeoff ? 📈🚀 According to analysts, it is totally undervalued. Important data will be released at ASH 2025 in early December. Can this data propel the company into a new era? The company wants to expand. The company's sales are increasing. high liquid assets of over USD …

CTXR 🟢Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting🚀🚀🚀 https://finance.yahoo.com/news/citius-oncology-exhibit-67th-american-130000466.html

$INAB, are you looking for a seriously undervalued biotech with compelling science? [https://www.biostockinfo.com/broken-stock-working-drug-in8bio-inab-valued-at-7m/](https://www.biostockinfo.com/broken-stock-working-drug-in8bio-inab-valued-at-7m/) I will make this very short, you can check the link for little more detail about the company. $INAB IN8bio is a nanocap biotech listed on Nasdaq. https://preview.redd.it/q5bk9t2hoe2g1.png?width=723&format=png&auto=webp&s=7653537df3baeaca5167b361acc1729eef0903d7 They’ve presented some incredible data that’s exceptionally rare for …

Buying: Tscan Therapeutics Inc ($TCRX) — Backed by Cash, RMAT Designation and an ASH Presentation Catalyst. **Strong Financial Position** TScan reported a cash, cash equivalents, and marketable securities balance of **$184.5 million** as of September 30, 2025. This strong cash position gives TScan a runway and reduces the immediate dilution …

Senti Biosciences - $SNTI short term bull case SNTI already demonstrated how violently it can move when expectations shift: in **December 2024 it spiked from $2 to $16 intraday** on nothing more than speculation and thin-float mechanics, without confirmed clinical data. This matters now because the upcoming **December 8 ASH …